Global healthcare company Novo Nordisk has announced plans to launch its obesity treatment drug, liraglutide, in the US by the end of 2014. Novo chief scientific officer Mads Thomsen was quoted by health24.com as saying that liraglutide ...
Tags: Obesity Drug, Medicine
The US FDA has approved Novo Nordisk Victoza (liraglutide [rDNA] injection) label to include data showing superior blood sugar control and weight reduction when compared to Januvia (sitagliptin). Label update also includes approval of ...
Tags: Label update, type 2 diabetes, Victoza